(Q39825232)

15 September 2017

1 reference

title

Podophyllotoxin derivative VP 16-213 (English)

1 reference

27 June 2022

1 reference

27 June 2022

1 reference

27 June 2022

author name string

A. M. Arnold

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A389478

27 June 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=389478

27 June 2022

publication date

1 January 1979

1 reference

full work available at URL

15 September 2017

http://link.springer.com/content/pdf/10.1007/BF00254976.pdf

file format

Portable Document Format

1 reference

http://link.springer.com/article/10.1007/BF00254976/fulltext.html

27 June 2022

1 reference

http://link.springer.com/content/pdf/10.1007/BF00254976

27 June 2022

1 reference

Cancer Chemotherapy and Pharmacology

27 June 2022

published in

1 reference

15 September 2017

3

1 reference

15 September 2017

71-80

1 reference

15 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00254976

15 September 2017

0 references

cites work

Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners

1 reference

12 December 2020

Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells

1 reference

12 December 2020

Interaction of drugs with microtubule proteins.

1 reference

12 December 2020

PTG, a new antineoplastic epipodophyllotoxin

1 reference

12 December 2020

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213)

1 reference

12 December 2020

Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours

1 reference

12 December 2020

Evaluation of VP-16-213 in malignant lymphoma and melanoma

1 reference

12 December 2020

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213

1 reference

12 December 2020

Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia

1 reference

12 December 2020

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

1 reference

12 December 2020

Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both

1 reference

12 December 2020

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer

1 reference

12 December 2020

PHASE I clinical trial of an oral solution of VP-16-213

1 reference

12 December 2020

The action of podophyllin and its fractions on marine eggs

1 reference

12 December 2020

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1 reference

12 December 2020

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

1 reference

12 December 2020

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung

1 reference

12 December 2020

Antimetastasis effect of two derivatives of epiposophyllotoxin in mice

1 reference

12 December 2020

4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action

1 reference

12 December 2020

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma

1 reference

12 December 2020

Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoietic cell lines.

1 reference

12 December 2020

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1 reference

12 December 2020

VM 26 and VP 16-213: a comparative analysis

1 reference

12 December 2020

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents

1 reference

12 December 2020

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1 reference

12 December 2020

VP 16-213 in acute myelogenous leukaemia

1 reference

12 December 2020

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

1 reference

12 December 2020

The Cytological Effects of Podophyllin

1 reference

12 December 2020

Human anticancer effect of podophyllum derivatives (SPG and SPI): a preliminary report

1 reference

12 December 2020

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1 reference

12 December 2020

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1 reference

12 December 2020

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1 reference

12 December 2020

Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors

1 reference

12 December 2020

EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA

1 reference

12 December 2020

Chemotherapy of small cell carcinoma of the lung with V. P. 16–213

1 reference

12 December 2020

Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures

1 reference

12 December 2020

Microtubules and axoplasmic transport. Inhibition of transport by podophyllotoxin: an interaction with microtubule protein

1 reference

12 December 2020

Autimitotic substances

1 reference

12 December 2020

Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076)

1 reference

12 December 2020

Treatment of small cell carcinoma: evolution and future directions

1 reference

12 December 2020

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease

1 reference

12 December 2020

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer

1 reference

12 December 2020

Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle

1 reference

12 December 2020

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules

1 reference

12 December 2020

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts

1 reference

12 December 2020

Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia

1 reference

12 December 2020

Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia

1 reference

12 December 2020

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213)

1 reference

12 December 2020

The Biochemical Events of Mitosis. II. The in Vivo and in Vitro Binding of Colchicine in Grasshopper Embryos and Its Possible Relation to Inhibition of Mitosis*

1 reference

12 December 2020

Tubulin binding affinities of podophyllotoxin and colchicine analogues

1 reference

12 December 2020

Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin

1 reference

12 December 2020

The biological effects and the chemical composition of podophyllin: a review

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro.

1 reference

12 December 2020

The association of a class of saltatory movements with microtubules in cultured cells

1 reference

12 December 2020

Nucleoside transport in mammalian cells. Inhibition by colchicine

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00254976

1 reference

15 September 2017

1 reference